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Abstract 
 
There is ample evidence in the international literature for 
pharmacist involvement in the prevention and management 
of cardiovascular disease (CVD) conditions in primary care. 
Systematic reviews and meta-analyses have confirmed the 
significant clinical benefits of pharmacist interventions for a 
range of CVD conditions and risk factors. Evidence generated 
in research studies of Australian community pharmacist 
involvement in CVD prevention and management is 
summarised in this article.  
Commonwealth funding through the Community Pharmacy 
Agreements has facilitated research to establish the feasibility 
and effectiveness of new models of primary care involving 
community pharmacists. Australian community pharmacists 
have been shown to effect positive clinical, humanistic and 
economic outcomes in patients with CVD conditions. 
Improvements in blood pressure, lipid levels, medication 
adherence and CVD risk have been demonstrated using 
different study designs. Satisfaction for GPs, pharmacists and 
consumers has also been reported. Perceived ‘turf’ 
encroachment, expertise of the pharmacist, space, time and 
remuneration are challenges to the implementation of disease 
management services involving community pharmacists.  
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Introduction 
Pharmacists in Australia have long undertaken roles in the 
prevention and management of CVD that extend beyond 
the traditional dispensing of medicines. These roles range 
from  provision  of  educational  materials,  through 
screening  and  monitoring  of  conditions  such  as  blood 
pressure,  to  interventions  in  areas  such  as  smoking 
cessation, lifestyle modification, medicines management 
and  medicines  adherence.  These  expanded  roles  are 
often informal in nature, implemented to varying extents 
between  pharmacies,  and  usually  are  neither 
remunerated  nor  systematically  integrated  within  the 
broader  primary  care  setting.
1-2  This  article  summarises 
the  evidence  generated  in  research  studies  regarding 
community  pharmacist  involvement  in  CVD  prevention 
and management.  
 
International evidence 
International  scientific  evidence  for  pharmacist 
involvement  in  CVD  interventions  has  increasingly 
emerged  in  recent  decades.  Consequently,  systematic 
reviews and meta-analyses of randomised controlled trial 
(RCT)  evidence  can  now  confirm  the  significant  clinical 
benefits of pharmacist interventions for a range of major 
disease states and preventive health activities related to 
diabetes  (significant  HbA1c  reductions),
3  smoking 
cessation  (improved  cessation  rates),
4-5  hyperlipidaemia 
(significantly reduced total cholesterol, and within-group 
significant LDL cholesterol reductions),
6 and hypertension 
(reduced  systolic  and  diastolic  levels).
7  While  this 
demonstrates the benefits of pharmacist intervention for 
several individual risk factors, it must be acknowledged 
that management of patients often requires concurrent 
consideration of multiple risk factors and interventions. 
To  address  this  gap  in  evidence  for  pharmacy,  more 
recent studies have examined the clinical effectiveness of 
pharmacists  delivering  multi-faceted  interventions  and 
addressing  multiple  cardiovascular  risk  factors.  For 
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example, Lee et al.
8 implemented a randomised clinical trial 
(RCT) in the United States involving individualised medication 
education, medication dispensing using medication aids, and 
regular  follow-up  with  clinical  pharmacists.  Compared  with 
usual  care,  pharmacist  interventions  significantly  improved 
systolic blood pressure (BP, -6.9 mmHg), medicine adherence 
and  medicine  persistence  for  an  elderly  population  taking 
multiple medications. Medication adherence measured via pill 
count increased markedly from 61% to 97% (P<0.001).  
 
Wu  et  al.
9  provided  RCT  data  to  demonstrate  significantly 
reduced  patient  mortality  following  delivery  of  a 
pharmaceutical care programme by telephone to patients in 
Hong Kong receiving polypharmacy (five or more drugs). The 
Number Needed to Treat (NNT) to prevent a single death in 
this clinically stable, elderly outpatient population was just 16 
– equivalent to a 41% relative risk reduction. It is important to 
note  that  while  this  was  a  general  patient  population,  the 
greatest  cause  of  mortality  was  from  CVD  and  changes  to 
cardiovascular medications following the intervention appear 
to  have  had  a  substantial  association  with  improved  risk 
profile. This intervention also reduced the median number of 
days spent in hospital each year (zero days versus three days, 
P=0.018),  and  fewer  patients  remained  non-compliant  with 
medications  (7%  versus  18%;  P<0.001).  Secondary  analysis 
shows a clear and significant association between worsening 
non-compliance with medications and mortality, highlighting 
the importance of this role for pharmacists. 
 
Pharmacists  have  also  engaged  extensively  in  the  specific 
management  of  more  complex  patients  with  CVD,  most 
notably those with heart failure. A systematic review of  12 
RCTs  indicates  that  pharmacist  care  is  associated  with  a 
significantly  reduced  rate  of  all-cause  hospitalisations  and 
heart failure hospitalisations, and non-significant reductions in 
mortality.
10  Included  trial  settings  were  hospital  outpatient 
departments, ambulatory care and community pharmacies. 
 
While  contributing  to  medicines  management,  recent 
international  studies  provide  good  reasons  to  suggest 
pharmacists can also contribute to broader CVD management 
as part of a primary care team. Notable examples include the 
Canadian SCRIP trial, which examined management of lipids in 
675 patients at high risk of vascular events and demonstrated 
a 13.4% relative reduction in LDL-cholesterol among high-risk 
patients with uncontrolled LDL-cholesterol, equivalent to an 
average reduction of 0.5 mmol/L.
11 The intervention aimed to 
implement  lipid  management  guidelines  through  patient 
education, investigation of other modifiable CVD risk factors, 
and  referral  to  physicians,  if  necessary  with  written 
documentation and recommendations. 
 
Several studies have assessed the capacity of community 
pharmacies  to  increase  their  involvement  in  screening 
activities.  Liu  et  al.
12  found  that  pharmacists  could 
competently identify patients at medium-high risk of CVD 
and  reliably  assess  their  10-year  absolute  risk  using  a 
validated scoring tool derived from the Framingham Heart 
Study. Other studies suggest that community pharmacists 
can identify significant numbers of people at risk of CVD, 
but  also  that  screening  programmes  in  community 
pharmacies are a useful way of targeting some hard to 
reach groups such as males, ethnic minorities and socially 
deprived  communities.
13-14  It  is  important  to  note  that 
these  screening  and  clinical  intervention  programmes 
were not designed to supplant the important role of the 
GP in patient cardiovascular care. Pharmacists appear to 
have acted within their competencies, and case detection 
programmes generally resulted in a large proportion of 
screened individuals being referred for in-depth medical 
examination  or  treatment.
13-14  The  desire  to  work  with 
medical  practitioners  rather  than  to  compete,  is 
underlined  by  an  increasing  number  of  studies 
highlighting the benefits of collaborative care processes. 
Collaborative  management  of  heart  failure  has  been 
found to produce even greater improvements in clinical 
outcomes  than  pharmacist-directed  care.
10  The  clinical 
benefits of team-based collaborative care compared with 
pharmacist-  or  GP-only  care  are  becoming  increasingly 
apparent.
15-16  
 
Evidence from Australia 
Over the past five to ten years, the community pharmacy 
profession  across  Australia  has  been  engaged  in 
generating hard evidence of the benefits of such roles in 
Australia.  Funding  from  the  Commonwealth-supported 
Community Pharmacy Agreements and other sources has 
enabled a concerted drive for research to establish the 
feasibility  and  effectiveness  of  new  models  of  primary 
care  involving  community  pharmacy.  Pharmacy 
interventions  have  been  shown  to  lead  to  improved 
clinical,  humanistic  and  economic  outcomes  in  patients 
with  cardiovascular  conditions.  Full  reports  of  projects 
funded  under  the  Community  Pharmacy  Agreement 
Research  and  Development  Program  are  available  at: 
http://www.5cpa.com.au/The key cardiovascular health 
findings  of  Australian  studies  carried  out  through 
community pharmacies are as follows:  
Hughes et al.
17 carried out the first Australian community 
pharmacy-based  hypertension  management  research  at 
six  community  pharmacies  located  in  the  Perth 
metropolitan  area.  Patients  (25  years  or  older)  were  Australasian Medical Journal  AMJ 2011, 4, 5, 266-272 
 
 
268 
recruited at the time of presentation of their first prescription 
for  an  antihypertensive  medication.  Enrolment  was  ceased 
after 12 months with a final cohort of 34 patients (11.3% of 
projected). Of the 34 patients enrolled, 13 participants – four 
in  the  control  group,  three  in  the  low  intervention  (three 
monthly  follow-up)  and  six  in  the  high  intervention  (six 
monthly  follow-up)  –  were  lost  to  follow  up.  Only  21 
participants (seven in each group) completed the trial. Less 
than 50% of the patients enrolled in the study were aware of 
the  BP  reading  on  which  their  doctor  had  based  their 
diagnosis of hypertension. The majority of subjects enrolled 
had Grade 1 or 2 hypertension as classified by the National 
Heart Foundation.  
All groups showed a reduction in BP with time. The mean BP 
in the control group decreased from 163/99 mm Hg to 137/87 
mm  Hg  (+/-  14.3/12.1);  mean  change:  26/12.  In  the  low 
intervention group mean BP decreased from 147/86 mm Hg 
to 138/83 mm Hg (+/- 4.9/9.0); mean change: 9/3 mm Hg. In 
the high intervention group it decreased from 131/82 mm Hg 
to 126/73 mm Hg (+/- 13.9/6.6); mean change: 5/9 mm Hg. 
The number of participants at target BP increased in all groups 
during the trial (0 to 2; 2 to 3; and 4 to 6 in the control, low 
intervention  and  high  intervention  groups,  respectively). 
Overall 42.9% of patients’ adherence was rated as very good 
and 33.3% as excellent. Both intervention groups showed a 
trend towards better adherence compared to controls.
17 
Stewart  et  al.
18  tested  an  intervention  package  to  enable 
community pharmacists to improve patient adherence and/or 
persistence with antihypertensive medications in a RCT with a 
view to improving BP control. Patients 18 years or above with 
primary  hypertension  who  had  been  dispensed  an 
antihypertensive in the previous six months were eligible to 
participate  in  the  Hypertension  Adherence  Program  in 
Pharmacy (HAPPY) Trial.
19 Pharmacies from three Australian 
states  –  Victoria,  Western  Australia  and  Tasmania  –  were 
randomised to Pharmacist Care Group (PCG; n = 29) or Usual 
Care Group (UCG; n = 26).  
Following  training,  PCG  pharmacists  offered  a  multi-faceted 
intervention to their patients (n=207) at baseline, three and 
six months. The intervention included home BP monitoring; 
training on self-monitoring of BP; motivational interviewing; 
medication use review; and prescription refill reminders (by 
SMS, telephone or mail). Pharmacist-initiated home medicine 
reviews,  dose  administration  aids,  referral  to  a  general 
practitioner and/or patient medication profile were offered, 
where  necessary.  UCG  participants  (n=188)  received  usual 
care.  There  were  no  significant  differences  between  the 
groups at baseline. Numbers of participants completing the 
study were 176 in the PCG and 178 in the UCG.  
In the HAPPY trial the number (%) of adherent patients as 
per  Morisky  scale
20  at  baseline  was  107  (57.5%)  in  the 
UCG and 112 (56.6%) in the PCG, which increased at six 
months to 111 (63.8%) and 127 (72.2%), respectively (p = 
0.09).
18 Reduction in systolic BP was significantly better in 
the PCG than the UCG (–10.0 mm Hg versus –4.6 mm Hg; 
p = 0.02). Reduction in BP of this magnitude is known to 
be  associated  with  reduced  incidence  of  heart  attacks, 
strokes  and  death  from  cardiovascular  disease.  The 
intervention  was  highly  cost-effective  as  the  cost  per 
Quality Adjusted Life year (QALY) gain of $6,322.58 was 
far greater than the benchmark $70,000 accepted by the 
Australian  government.  This  level  of  economic  viability 
has  also  been  demonstrated  in  other  disease  state 
management  trial  of  diabetes  and  asthma  care  in 
Australia.
21-22 
Emerson  et  al.
23  tested  the  health  impact  of  an  inter-
disciplinary  Continuous  Quality  Improvement  (CQI) 
approach in rural areas in a RCT using community Quality 
Use of Medicines (QUM) indicators. It involved a control 
group  (six  sites)  which  provided  ‘usual  care’,  a  low 
intervention  group  (one  site)  to  test  the  impact  of 
collaborative interventions without the use of indicators, 
and  a  high  intervention  group  (two  sites),  to  test  the 
predictive validity of those indicators. Participants were 
aged between 40–65 years, on cardiovascular medication, 
and with a 10% or higher 10-year CVD risk. Recruitment 
and point of care testing for coronary heart disease (CHD) 
risk  were  undertaken  through  community  pharmacies. 
The pharmacists and GPs were encouraged to collaborate 
to implement a range of evidence-based interventions to 
reduce  CHD  risk  in  the  low  intervention  group  over  12 
months, whereas the control group continued to receive 
usual  care.  Regular  meetings  between  pharmacists  and 
GPs to discuss the results of all indicators complied from 
data collected prior to the meetings, and the delivery of 
interventions to  increase the number of indicators met 
for  enrolled  patients  occurred  in  the  high  intervention 
sites. Changes in key clinical results such as CHD risk, BP, 
lipids,  weight,  smoking  and  diabetes  status  were 
measured approximately 16 months after recruitment.  
A total of 229 participants were recruited – 101 to the 
high intervention group, 60 to the low intervention group 
and 68 to the control group. Pharmacists provided 324 
interventions  (e.g.  BP  checking,  medication  compliance 
assessment, nutrition and exercise advice) to participants 
in the two intervention groups. The mean 10-year CHD 
risk change score for  the high intervention group patients 
was a reduction in risk of -2.33 (a change from 18.3% to 
16.0%; p=0.007), while the changes in control group and  Australasian Medical Journal  AMJ 2011, 4, 5, 266-272 
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low intervention groups failed to reach statistical significance 
(-0.17%;  p=0.87  and  +1.47%;  p=0.23,  respectively).  The 
reduction in the high intervention group equated to a 13% 
reduction  from  baseline  score.  There  was  a  significant 
difference in the effect between groups (p=0.04). 
Aslani  et  al.
24  carried  out  a  repeated-measures  RCT  to 
develop, implement and evaluate a new service in community 
pharmacy for conducting therapeutic outcomes monitoring in 
patients  with  dyslipidaemia  and  to  promote  adherence  to 
medication  therapy.  Patients  were  eligible  if  they  were  18 
years or older, able to fluently speak and read English, and 
taking a lipid-lowering medicine for at least one month prior 
to  enrolment  in  study.  Pharmacists  (n=38)  were  trained  in 
study  conduct,  and  given  continuing  professional  education 
on  ischaemic  heart  disease  and  lipid  management. 
Intervention  pharmacists  were  also  trained  on  the 
intervention.  
Intervention  group  patients  attended  the  pharmacy  at 
baseline and approximately every three months. At each visit, 
total blood cholesterol levels (non-fasting) were measured by 
pharmacists using a point of care testing device. After lipid 
levels  were  taken,results  were  provided  to  the  patient. 
Pharmacists  assessed  each  consumer  individually,  and 
developed  a  targeted  strategy  to  address  their  barriers  to 
adherence.  Control  group  patients  also  attended  the 
pharmacy, but only had their blood lipid levels measured and 
reported to them, and completed the questionnaire.  
Seventeen  pharmacists  recruited  142  patients  (97 
completions:  49  control,  48  intervention).  Most  patients 
missed either the third or last visit, thus data at visits three 
and four were combined. Patients in the intervention group 
achieved a significantly greater reduction in total cholesterol 
levels  (0.5  mmol/L)  compared  to  those  in  the  comparison 
group  (0.01  mmol/L)  over  the  study  period  (p<0.05).  There 
was  a  9%  reduction  in  the  total  cholesterol  levels  of  the 
intervention group. Intervention group patients lowered their 
total cholesterol level by an average of 6.7% over the study 
period, which translates to ∼10% reduction in CHD mortality 
risk and an expected ∼7% reduction in total mortality risk. No 
changes  in  medicine  adherence  scores  were  observed 
although there was an improvement in participants’ exercise 
and eating habits. There were no differences between the two 
groups’ hospital admissions and GP visits during the course of 
the study. For patients with an average blood lipid reading of 
~5 mmol/L, the cost to achieve an average 10% lowering of 
cholesterol  was  between  $293  and  $356  including  start-up 
costs, and approximately $178 for an ongoing service delivery.  
Mc  Namara  et  al.
25-26  tested  a  pilot  model  for  primary 
prevention  of  CVD  in  community  pharmacy  aimed  at 
improving  quality  of  care.  Pharmacists  from  10 
pharmacies  received  training  in  CVD  risk  factor 
management  and  facilitating  patient  lifestyle 
modification. They recruited 70 participants aged 50–74 
years, taking medicines for BP or cholesterol, and without 
diabetes  or  CVD.  At  baseline,  research  assistants 
conducted  a  clinical  assessment  of  risk  factors,  and 
conducted  interviews  to  assess  health  behaviours, 
medicine use and related issues. Data was analysed by a 
consultant  pharmacist  (credentialed  to  undertake 
medication reviews) and summary reports produced, with 
recommendations  and  targets  for  risk  reduction.  These 
were  addressed  by  patients  and  their  community 
pharmacists over five monthly sessions. 
At  follow  up,  the  relative  risk  reduction  for  CVD  onset 
over the next five years was 24% (p<0.001), contributed 
to by reductions in mean systolic BP (7 mmHg), diastolic 
BP  (5  mmHg),  total:HDL  cholesterol  ratio  (–0.2),  waist 
circumference (–2 cm in males, –0.7 cm in females) and 
other  risk  factors.  Several  key  health  behaviours 
improved,  including  diet  quality  and  physical  activity 
levels.  Prevalence  of  non-adherence  to  cardiovascular 
medicines dropped in absolute terms by 16% to 22%. 
Hourihan  et  al.
27  developed  a  pharmacy  based  health 
promotion and screening model for a rural population at 
risk of CVD. A total of 204 participants attended the initial 
screening; 89% had at least one modifiable risk factor for 
CVD and 80% received healthy lifestyle advice from the 
pharmacist.  Dietary  advice  was  delivered  to  70%  of 
participants,  exercise  advice  to  42%  and  smoking 
cessation advice to 8%. 
Peterson  et  al.
28  carried  out  CVD  risk  profiling  of 
individuals  aged  30 years  and  older  without  diagnosed 
heart disease. The risk profiling was performed by three 
trained research pharmacists in a convenience sample of 
14 community pharmacies, predominantly in rural areas 
of Tasmania and Northern Queensland. Six hundred and 
forty  subjects  with  a  median  age  of  54 years  were 
screened  for  CVD  risk  factors.  Participants  were 
considered at risk of CVD because of an estimated 10-year 
CVD risk greater than 15%, or because of detection of one 
or more abnormal test results (i.e. systolic BP greater than 
or equal to 140 mmHg; diastolic BP greater than or equal 
to 90 mmHg; total cholesterol greater than or  equal to 
5.5 mmol/l; HDL cholesterol below 1.0 mmol/l or random 
blood glucose greater than or equal to 8 mmol/l), were 
asked  to  see  their  GP  for  further  assessment  or  Australasian Medical Journal  AMJ 2011, 4, 5, 266-272 
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management. A copy of the results was sent to the nominated 
GP with any necessary recommendations.   
The  estimated  10-year  CVD  risk  of  the  subjects  screened 
ranged  from  0.2%  to  61.0%  (median = 9.5%).  More  than  a 
quarter  (28.1%)  of  the  subjects  was  considered  to  be  at 
increased  risk  of  cardiovascular  events.  A  total  of  467 
individuals (73% of those screened) who were considered at 
increased  risk  because  of  their  estimated  10-year  CVD  risk 
(n = 180)  or  because  of  one  or  more  abnormally  high  test 
results (n = 287) were advised to consult their doctor. Overall, 
the survey participants had a reasonable knowledge of CVD 
risk  factors,  with  a  mean  score  of  15.8 ± 2.2  (maximum 
score = 20) in the pre-consultation quiz. At the three-month 
follow-up, there was a small, but significant, improvement in 
the mean risk factor knowledge score (16.7 ± 2.4) for the 346 
participants  who  returned  questionnaires  (p< 0.0001).  The 
advice  provided  during  the  pharmacy  consultation,  or  the 
screening itself, also appeared to have behavioural benefits, 
with 191 subjects (55% of respondents) reporting one or more 
lifestyle  changes;  31.8%  reported  increased  exercise,  16.4% 
weight loss, 29.8% improved diet and 3.6% had quit smoking.  
In general, the process was well accepted by participants, with 
71%  of  the  346  respondents  regarding  the  screening  as 
worthwhile, and 98% rating the consultation as good (30%) or 
excellent (68%). The majority regarded community pharmacy 
as an appropriate place for cardiovascular risk screening (97%) 
and  felt  that  this  could  be  a  routine  service  offered  by 
community pharmacists (90.5%). Assuming approximately 10 
subjects  per  pharmacy  would  be  screened  per  week,  this 
programme  in  one  community  pharmacy  over  five  years 
would  screen  2,500  people  at  a  cost  to  the  pharmacy  of 
$62,864. Of the 2,500 screened individuals, 700 (with risk of 
CVD exceeding 15% over 10 years) would be referred and 315 
would  receive  an  intervention,  potentially  averting  10 
cardiovascular events over five years. In one pharmacy, the 
screening  program  would  thereby  prevent  three  premature 
deaths  during  five  years.  Against  the  previously  described 
international backdrop, in 2005 Peterson et al.
29 developed 
the  Pharmacy  Cardiovascular  Health  Model  in  Australia  to 
identify  how  the  community  pharmacy  profession  could 
optimise  its  contribution  to  the  prevention,  detection  and 
management  of  CVD  in  Australia.  The  Pharmacy 
Cardiovascular Health Care  Model proposed by Peterson et 
al.
29 has the following priority areas: 
•  Public/preventive health promotion. 
•  Continuum of care. 
•  High-risk patient referral. 
•  Compliance with therapy. 
•  Medication management and reviews.  
To assist in developing the model, a 15-minute computer-
assisted  telephone  survey  of  505  households  was 
conducted  across  Australia  (metropolitan,  rural  and 
remote)  to  gauge  public  willingness  to  embrace 
involvement  of  community  pharmacists  in  CVD 
prevention/management.  The  sample  (aged  over  29 
years) was screened to include only those who had visited 
a pharmacy in the previous month, and had a quota of 
50% with CVD. There was a high level of satisfaction with 
the  quality  of  service  provided  by  regularly  visited 
pharmacies;  however,  there  appeared  to  be  a  lack  of 
awareness  amongst  consumers  about  the  skills  and 
capabilities  of  pharmacists  and  of  services  available 
through pharmacies. Not surprisingly, the most accepted 
role for community pharmacists was the optimisation of 
medicines  use,  with  90%  willing  to  seek  advice  on 
medication  use  from  pharmacists.  Many  respondents 
believed  that  pharmacists  are  capable  of  providing 
screening  or  testing  for  hypertension,  diabetes  and 
cholesterol, with the majority indicating that they would 
be likely to use these screening services if provided.  The 
value  of  this  risk  factor  and  disease  screening  role  in 
community  pharmacies  has  been  confirmed  in  other 
studies.
30-31  A  majority  also  believed  pharmacists  to  be 
competent to provide advice on lifestyle changes (weight 
loss, smoking, alcohol intake etc.) and information about 
CVDs  and  their  management.  Overall,  these  findings 
suggest  sufficient  public  support  for  the  profession  to 
start  engaging  broadly  in  different  activities  supporting 
the roles listed above. 
 
In  developing  and  implementing  disease  state 
management  programmes,  including  those  directed  at 
improving cardiovascular health, many researchers have 
consulted  stakeholders  to  ascertain  opinions  regarding 
feasibility  and  acceptability  of  such  programmes. 
Stakeholders  have  commonly  included  GPs,  community 
pharmacists  and  consumers.  Opinions  are  generally 
consistent  across  the  various  programmes.  The  general 
consensus  is  that  both  pharmacists  and  general 
practitioners  have  reservations  about  the  feasibility  of 
such  programmes  prior  to  the  trials.  Recurring  themes 
include  perceived  need  for  the  service,  potential  ‘turf’ 
encroachment, expertise of the pharmacist, space, time 
and remuneration.
17-18, 32  
 
GPs have emphasised that they would like to be assured 
that patients would be referred back to them for issues 
that  are  beyond  the  pharmacists’  capabilities. 
Hypertension  largely  being  an  asymptomatic  condition, 
consumers  may  not  be  motivated  to  have  regular  GP 
consultations  unless  encouraged  by  their  health  Australasian Medical Journal  AMJ 2011, 4, 5, 266-272 
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professionals. BP monitoring between GP visits, either at the 
pharmacy or at home by the patient, might also be beneficial. 
Lack of adequate space within some pharmacies to conduct 
private  consultations  was  mentioned  as  a  major  barrier  to 
offering  any  pharmacy  service  focusing  on  chronic  disease 
management, and needs to be addressed within this setting to 
ensure patient confidentiality. 
 
Pharmacist and consumer satisfaction with pharmacy services 
in studies (e.g. HAPPY trial
18) has been high; most could not 
think  of  any  ways  to  improve  the  service.  It  was  thought 
appropriate that pharmacists should provide the service as it 
was commonly recognised that GP resources were stretched 
and  extension  of  their  current  services  may  be  not  be 
possible.  Pharmacies  were  seen  as  a  relaxing  environment, 
and pharmacists seen as approachable. For the same reason, 
expecting  substantial  pharmacist–GP  collaboration  in 
delivering such an intervention, although ideal, may not be 
feasible.  However,  while  GPs  generally  believed  that  a 
pharmacist-led educational programme would be beneficial to 
patients, it was suggested that a more formal, personalised 
communication between the pharmacist and the GP would be 
helpful  e.g.  via  referral  slips,  preferably  by  fax  to  facilitate 
entry of information into the patient record. Consumers rated 
the most important components as monitoring their own BP 
regularly  and  the  education  they  received  from  the 
pharmacists.  Most consumers felt they had been given the 
tools to have a greater input into their BP management.  The 
main facilitator for successful implementation of a community 
pharmacy disease state management programme was seen to 
be  remuneration  for  pharmacists.  Without  this,  pharmacy 
staff  would  not  have  time  available  for  prolonged 
consultations.  Team  work  involving  consumers,  GPs,  other 
health professionals and pharmacists was also thought to be 
essential  for  the  success  of  collaborative  disease  state 
management programmes.  
 
Conclusion 
There is mounting clear evidence of the positive potential for 
collaborations  between  GPs  and  community  pharmacists  in 
the  management  and  prevention  of  CVD.  The  evidence 
involves  improvement  in  clinical  markers,  improvements  in 
quality  of  life  in  some  conditions,  satisfaction  for  GPs, 
pharmacists  and  consumers  –  and  all  at  an  economically 
viable cost. The challenges that lie ahead, in the climate of 
primary  healthcare  reform  include  fostering  of  the  team 
approach and development of a sustainable funding model. 
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